Induced pluripotent stem (iPS) cells are a type of stem cell that can be generated directly from adult cells. They were first developed in 2006 by Shinya Yamanaka and his team. iPS cells are engineered by reprogramming adult cells, such as skin cells, to revert to a pluripotent state, meaning they have the ability to differentiate into any cell type in the body. This reprogramming is typically achieved by introducing a combination of specific genes or gene factors into the adult cells, which resets their developmental clock. [Read more…]
The Pipeline for iPSC-Derived Cell Therapeutics in 2024
Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
Fiocruz and Caring Cross To Offer Drastically More Affordable CAR-T Therapy in Brazil and Latin America
Local production will permit CAR-T treatment to be available free of charge to patients.
The cost to the Brazilian public health system will be slashed to 10% of the amount currently charged in Europe and the USA (only US$35,000 per dose).
RIO DE JANEIRO and GAITHERSBURG, Md., March 26, 2024 — Fundação Oswaldo Cruz (Fiocruz), a foundation from the Brazilian government’s Ministry of Health, and Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to advanced medicinal cures for all patients, everywhere, today announced a collaboration to develop local manufacturing of chimeric antigen receptor (CAR)-T cell and stem cell gene therapies for oncology, infectious, and genetic diseases in Brazil, including CAR-T cell therapies for leukemia, lymphoma, and HIV infection. [Read more…]
What Is An RMAT? List of Publicly Announced RMAT Designations (90)
To date, what number of U.S. FDA-approved RMATs have been issued and to whom have they been awarded?
The answer is that 90 RMAT (Regenerative Medicine Advanced Therapy) designations have been publicly announced by biotech and pharma companies. However, the FDA states it has received 248 requests and issued 101, which means that a handful are not yet public knowledge. Therefore, a few companies are operating in stealth mode with regard to their RMAT designations and approximately 41% of RMAT applications get approved (101 approvals / 248 applications = 40.7%). [Read more…]
PeptiGrowth Inc. is launching a Novel Synthetic Peptide TPO-alternative peptide (TPOR agonist)
March 26, 2024, Chiyoda-ku, Tokyo – PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel synthetic peptide called “TPO alternative peptide (TPOR agonist)” which has equivalent function to recombinant TPO (Thrombopoietin). This product will be on the market at the end of March 2024. [Read more…]
- 1
- 2
- 3
- …
- 47
- Next Page »